首页> 外文期刊>Indian heart journal >Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain
【24h】

Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain

机译:心脏型脂肪酸结合蛋白(H-FABP)作为急性胸痛患者的早期诊断生物标志物

获取原文
获取外文期刊封面目录资料

摘要

Background: Heart-type fatty acid-binding protein (H-FABP) is an emerging biomarker, which was found to be sensitive for the early diagnosis of acute myocardial infarction (AMI). We prospectively investigated the usefulness of H-FABP determination for the evaluation of acute chest pain in patients arriving at the emergency department. Methods: Fifty-four patients presenting with acute ischemic chest pain were evaluated. H-FABP was estimated at admission using latex-enhanced immunoturbidimetric assay. Serial cardiac troponin I (cTnI), creatinine kinase-MB (CK-MB) determination, ischemia workup with stress testing, and/or coronary angiogram (CAG) were performed according to standard protocols. Results: The sensitivity and specificity of H-FABP was 89.7% and 68%, for cTnI it was 62.1% and 100%, and for CK-MB it was 44.8% and 92%, respectively for diagnosis of AMI. The sensitivity of H-FABP was found to be far superior to initial cTnI and CK-MB, for those seen within 6h (100% vs. 46.1%, 33% respectively). On further evaluation of patients with positive H-FABP and negative cTnI, 71.4% of the patients had significant lesion on CAG, indicating ischemic cause of H-FABP elevation. Six patients with normal cTnI and CK-MB with high H-FABP had ST elevation on subsequent ECGs and were taken for primary angioplasty. Conclusion: H-FABP is a highly sensitive biomarker for the early diagnosis of AMI. H-FABP as early marker and cTnI as late marker would be the ideal combination to cover the complete diagnostic window for AMI. Detection of myocardial injury by H-FABP may also be applied in patients with unstable angina. H-FABP can also be used as a marker for early detection of STEMI before the ECG changes become apparent.
机译:背景:心脏型脂肪酸结合蛋白(H-FABP)是新兴的生物标志物,被发现对急性心肌梗塞(AMI)的早期诊断敏感。我们前瞻性地研究了H-FABP测定对评估急诊患者急性胸痛的有用性。方法:对54例急性缺血性胸痛患者进行评估。入院时使用乳胶增强免疫比浊法评估H-FABP。根据标准方案,进行了系列心肌肌钙蛋白I(cTnI),肌酐激酶-MB(CK-MB)测定,通过压力测试的局部缺血检查和/或冠状动脉造影(CAG)。结果:H-FABP对AMI诊断的敏感性分别为89.7%和68%,cTnI为62.1%和100%,CK-MB为44.8%和92%。对于在6h内见到的H-FABP,其敏感性远远优于初始cTnI和CK-MB(分别为100%和46.1%,33%)。在对H-FABP阳性和cTnI阴性的患者进行进一步评估时,有71.4%的患者CAG有明显病变,表明是H-FABP升高的缺血原因。 cTnI和CK-MB正常且H-FABP高的6例患者随后的ECG出现ST升高,并接受了原发性血管成形术。结论:H-FABP是AMI早期诊断的高度敏感的生物标志物。 H-FABP作为早期标志物,而cTnI作为晚期标志物将是覆盖AMI完整诊断窗口的理想组合。 H-FABP检测心肌损伤也可用于不稳定型心绞痛患者。 H-FABP也可用作在ECG变化变得明显之前早期检测STEMI的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号